Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia

L. Melillo; N. Cascavilla; G. Lombardi; M. Carotenuto; P. Musto

Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia

L. Melillo, N. Cascavilla, G. Lombardi, M. Carotenuto, P. Musto

Research output: Contribution to journal › Article › peer-review

Abstract

Serum levels of β₂-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x10⁹/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or

Original language	English
Pages (from-to)	1076-1078
Number of pages	3
Journal	Leukemia
Volume	6
Issue number	10
Publication status	Published - 1992

ASJC Scopus subject areas

Cancer Research
Hematology

Access to Document

Fingerprint Dive into the research topics of 'Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this

@article{b2b838c24bc24b83b0a59e08656c7efa,

title = "Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia",

abstract = "Serum levels of β2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x109/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or ",

author = "L. Melillo and N. Cascavilla and G. Lombardi and M. Carotenuto and P. Musto",

year = "1992",

language = "English",

volume = "6",

pages = "1076--1078",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia

AU - Melillo, L.

AU - Cascavilla, N.

AU - Lombardi, G.

AU - Carotenuto, M.

AU - Musto, P.

PY - 1992

Y1 - 1992

N2 - Serum levels of β2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x109/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or

AB - Serum levels of β2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x109/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or

UR - http://www.scopus.com/inward/record.url?scp=0026742794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026742794&partnerID=8YFLogxK

M3 - Article

C2 - 1405762

AN - SCOPUS:0026742794

VL - 6

SP - 1076

EP - 1078

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -